哈药股份(600664.SH)：所属企业获得化学原料药上市申请批准通知书

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug, Ferric Succinate, from the National Medical Products Administration, indicating compliance with national drug review technical standards [1] Group 1: Company Developments - The approval of Ferric Succinate marks a significant advancement in the company's layout in the raw material drug sector, enabling self-control over related raw materials [1] - This approval will further solidify the company's integrated development strategy of raw materials and formulations, contributing to a richer product structure [1]